Callan Family Office LLC Purchases Shares of 7,974 The Cooper Companies, Inc. $COO

Callan Family Office LLC purchased a new stake in The Cooper Companies, Inc. (NASDAQ:COO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,974 shares of the medical device company’s stock, valued at approximately $572,000.

A number of other hedge funds also recently made changes to their positions in COO. Avalon Trust Co bought a new stake in Cooper Companies in the second quarter valued at approximately $25,000. Root Financial Partners LLC raised its holdings in Cooper Companies by 104.5% during the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after purchasing an additional 162 shares during the last quarter. SJS Investment Consulting Inc. raised its holdings in Cooper Companies by 107.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock worth $26,000 after purchasing an additional 187 shares during the last quarter. Elevation Wealth Partners LLC lifted its position in shares of Cooper Companies by 1,136.4% in the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after purchasing an additional 375 shares during the period. Finally, J.Safra Asset Management Corp acquired a new position in shares of Cooper Companies in the 2nd quarter worth approximately $32,000. 24.39% of the stock is currently owned by institutional investors.

Cooper Companies Stock Performance

Shares of COO stock opened at $73.04 on Wednesday. The firm has a 50 day moving average of $72.20 and a 200-day moving average of $71.01. The company has a market cap of $14.24 billion, a price-to-earnings ratio of 61.90, a price-to-earnings-growth ratio of 1.98 and a beta of 0.83. The company has a quick ratio of 0.78, a current ratio of 1.27 and a debt-to-equity ratio of 0.23. The Cooper Companies, Inc. has a 52 week low of $58.89 and a 52 week high of $89.83.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.11. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. Cooper Companies’s quarterly revenue was up 7.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.96 EPS. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. On average, equities analysts forecast that The Cooper Companies, Inc. will post 4.63 earnings per share for the current year.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Traders purchased 4,056 call options on COO, roughly 411% above the typical daily volume of 794 contracts. This points to increased speculative bullish interest, although options activity alone does not guarantee a sustained stock advance.
• Neutral Sentiment: The latest short-interest report lists zero shares sold short and a 0.0-day short-interest ratio, but it also describes the change as “NaN” from a prior total of zero. The figures appear inconsistent and provide little useful information about investor positioning. Short Interest Report
• Negative Sentiment: COO’s valuation remains demanding, with a reported P/E ratio near 62. That can make the shares more sensitive to profit-taking or a lack of fresh positive catalysts, even though the company recently exceeded quarterly earnings and revenue expectations and reported year-over-year revenue growth.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Cooper Companies from $80.00 to $71.00 and set a “neutral” rating for the company in a research report on Friday, June 5th. Wall Street Zen upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a report on Sunday, June 21st. Needham & Company LLC cut their price target on shares of Cooper Companies from $101.00 to $86.00 and set a “buy” rating on the stock in a research report on Friday, June 5th. Wells Fargo & Company reiterated a “sell” rating and set a $66.00 price target (down from $82.00) on shares of Cooper Companies in a report on Friday, June 5th. Finally, BNP Paribas Exane lowered their price objective on Cooper Companies from $95.00 to $92.00 and set an “outperform” rating for the company in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $81.64.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.